Post-Traumatic Hypopituitarism in Traumatic Brain Injury

Disease/Disorder

Definition

Post-traumatic hypopituitarism (PTHP) is a disorder resulting from brain trauma, characterized by partial or complete deficiency of one or more pituitary hormones due to damage to the pituitary gland or hypothalamic-pituitary axis.¹ This dysfunction, which may be transient or permanent, affects the hypothalamic-pituitary-peripheral hormone axes and results in deficiencies of growth hormone (GH), gonadotropins [follicle-stimulating hormone (FSH) and luteinizing hormone (LH)], adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), prolactin, and antidiuretic hormone (ADH).¹

Etiology

PTHP results from direct mechanical injury to the hypothalamus and pituitary gland, vascular compromise (e.g., pituitary stalk transection, portal vein damage), ischemia, and secondary insults such as hypoxia, hypotension, and increased intracranial pressure. Neuroinflammation and autoimmune responses may further contribute to pituitary damage. Genetic predisposition and circulating autoantibodies have also been implicated.¹

Epidemiology including risk factors and primary prevention

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. The most common causes include falls, motor vehicle accidents, sports injuries, violence, and blast-related trauma.² Neuroendocrine dysfunction is a common, underdiagnosed, and clinically significant complication of TBI. The prevalence of hypopituitarism post-TBI varies widely (5–70%) and changes over time, with pooled estimates around 27.5–32%.^2,3 

Risk factors for neuroendocrine dysfunction include

• Severity of TBI
• Advanced age
• ICU admission
• Skull fractures
• Brain edema³ 

Primary prevention focuses on minimizing TBI risk through public health measures (e.g., fall prevention, road safety, protective equipment in sports) and optimizing acute management to reduce secondary brain injury.

Patho-anatomy/physiology

The hypothalamic-pituitary axis is highly vulnerable to mechanical and vascular injury. Damage may occur via

• Direct trauma to the pituitary or hypothalamus
• Vascular injury (e.g., stalk transection, portal vein disruption)
• Ischemic infarction of the adenohypophysis
• Secondary insults (hypoxia, hypotension, increased intracranial pressure)
• Neuroinflammatory processes leading to chronic dysfunction¹ 

Disease progression including natural history, disease phases or stages, disease trajectory (clinical features and presentation over time)

Neuroendocrine dysfunction after TBI is characterized by a variable and evolving course, with acute and chronic phases marked by distinct patterns of pituitary hormone deficiencies.

• Acute phase dysfunction: In the acute phase, up to 80% of patients may show evidence of gonadotropin deficiency, 13-40% ADH abnormalities [diabetes insipidus or syndrome of inappropriate ADH secretion (SIADH)], 2%-30% GH deficiency, and 16% ACTH deficiency.^2,4 Adrenal insufficiency and ADH deficiency are life-threatening and require prompt recognition and management.¹ Diagnosis is challenging due to overlapping symptoms and altered hormone binding/metabolism in critical illness, and many of these deficiencies are transient.^1,4
• Chronic phase dysfunction: Chronic hypopituitarism affects approximately 25%-32% of long-term TBI survivors.^4,5 GH deficiency is most common, followed by gonadotropin deficiencies, with ACTH, TSH, and ADH abnormalities occurring less frequently.^2,5 Clinical presentation depends on the type of hormone deficiency, as discussed in the following section.

Some patients may recover pituitary function over time, while some symptoms persist, and others may develop new deficiencies years after injury.¹ 

Specific secondary or associated conditions and complications

PTHP after TBI can affect multiple aspects of an individual’s health and recovery, often requiring additional support and management.

• GH deficiency may lead to persistent fatigue, reduced exercise capacity, impaired cognitive function, dyslipidemia, osteoporosis, and changes in body composition, such as increased fat mass and decreased muscle mass. These symptoms can hinder rehabilitation progress and overall quality of life (QoL).
• Gonadotropin (FSH/LH) deficiency can cause sexual dysfunction, infertility, menstrual irregularities, and decreased libido. These issues may contribute to psychological distress and may require management, including hormone replacement therapy when appropriate.
• ACTH deficiency, as a result of TBI, leads to secondary adrenal insufficiency, which may present as severe fatigue, hypotension, hypoglycemia, hyponatremia, weight loss, and generalized weakness. Treatment involves prompt glucocorticoid replacement therapy to address secondary adrenal insufficiency due to ACTH deficiency following TBI.
• TSH deficiency can manifest as fatigue, weight gain, cold intolerance, bradycardia, and depression. These symptoms, including neurocognitive deficits and mood disturbances, may overlap with other TBI-related complaints, complicating diagnosis and necessitating careful endocrine evaluation.
• ADH deficiency may lead to central diabetes insipidus (CDI), characterized by excessive thirst, urination, and hypernatremia; conversely, SIADH leads to hyponatremia and risk of seizures or cerebral edema. Both conditions require close monitoring and tailored management.²

Overall, the presence of neuroendocrine dysfunction after TBI can substantially increase morbidity and mortality, underscoring the importance of early recognition, comprehensive assessment, and individualized management to optimize recovery and QoL.²

Essentials of Assessment

History

A detailed history is critical when evaluating suspected neuroendocrine dysfunction in individuals with TBI. Clinicians should establish a clear chronology of symptoms, emphasizing changes from the patient’s pre-injury baseline, and recognizing that hormonal disturbances follow a variable course after injury. Because symptoms of TBI overlap extensively with manifestations of hypopituitarism, a high index of suspicion is required.²

A comprehensive history should identify

• TBI characteristics: Clarify the mechanism and severity of injury, presence of skull fractures, intracranial hemorrhage, cerebral edema, need for ICU admission, and time elapsed since the event, as these are risk factors for PTHP.^2,3
• Symptoms of PTHP: Screen broadly for features suggestive of hypopituitarism, including fatigue, weight changes and altered body composition, cold intolerance, decreased libido, erectile dysfunction, menstrual irregularities, cognitive slowing, mood and sleep disturbances, polydipsia, polyuria, and poor functional recovery.²
• Medication exposures: Certain medications, including benzodiazepines, opioids, and anti-epileptic agents, may mimic pituitary dysfunction and should be carefully considered.¹

Because individuals with TBI frequently have impaired self-awareness or communication difficulties, collateral history from caregivers is often invaluable. Structured symptom inventories at follow-up visits can help illustrate the severity of post-TBI symptoms, sleep, and mood disturbances.

Physical examination

Physical exam findings in PTHP after TBI are often subtle and nonspecific, particularly in the chronic phase. However, careful examination can offer clues toward specific pituitary axes.

Key components include

• Vital signs: Hypotension and orthostatic instability may signal adrenal insufficiency; bradycardia and hypothermia may reflect hypothyroidism.
• Appearance: Increased adiposity and reduced muscle mass may be consistent with GHD. Hair loss and weight gain may be associated with hypothyroidism. Features such as pubertal delay, regression of secondary sexual characteristics, diminished muscle mass, and hair loss may raise concern for gonadotropin deficiency.
• Musculoskeletal assessment: Proximal muscle weakness, reduced exercise tolerance, and generalized weakness may reflect GHD, hypothyroidism, or ACTH deficiency.²
• Psychiatric: A flat, anxious, or depressed affect may be linked to underlying GHD.⁶

Because many physical manifestations of PTHP overlap with TBI-related deconditioning and neuropsychiatric sequelae, the examination should be interpreted within the broader clinical context.

Laboratory studies

Laboratory evaluation plays a critical role in identifying PTHP after TBI. Decreased levels of morning cortisol may indicate ACTH deficiency, while measurement of urea, creatinine, and electrolytes help identify disorders of vasopressin secretion. Central hypothyroidism is characterized by normal or low levels of both TSH and free thyroxine (T4). Gonadotropin deficiency in men is suggested by decreased LH/FSH, testosterone, sex-hormone binding globulin, and albumin. In pre-menopausal women, low LH/FSH and estradiol indicate gonadotropin deficiency, whereas post-menopausal women with low FSH may have underlying gonadotropin deficiency.⁷

IGF-1 is frequently utilized as an initial screening test for GHD, where low or low-normal levels relative to age and sex norms may suggest GHD. However, IGF-1 has limited sensitivity and specificity, and confirmatory stimulation testing is required to diagnose GHD, unless three or more pituitary hormone deficiencies are present with and IGF-1 z-score < -2.⁸

Glucagon stimulation testing

The glucagon stimulation test (GST) is a commonly used dynamic test to confirm GHD. GST involves intramuscular administration of glucagon, with subsequent measurement of glucose and GH levels at every 30-minutes for three to four hours. Limitations of the GST include the extended test duration, that results are affected by patient BMI, and the need for intramuscular hormone administration. Advantages include that the GST is a widely available and safe alternative to the ITT, that does not induce significant hypoglycemia.⁸  

Insulin tolerance testing

The insulin tolerance test (ITT) is a dynamic test that can assess both GHD and ACTH deficiency. ITT involves IV administration of insulin, with subsequent blood draws to measure glucose, cortisol, and GH at specified intervals. The ITT is a highly sensitive and specific confirmatory test for GHD and ACTH deficiency. However, ITT has the potential for profound hypoglycemia, requiring close supervision, and is contraindicated in patients with ischemic heart disease, arrhythmias, and seizure disorders.⁸

Imaging

Imaging plays a supportive but not primary role in the assessment of PTHP after TBI. The diagnosis of PTHP is primarily clinical and biochemical, though imaging may be useful in identifying relevant structural lesions. Prior research has demonstrated inconsistent value of acute or delayed CT findings in predicting neuroendocrine dysfunction.¹ MRI of the brain after TBI may reveal edematous changes of the pituitary, in the absence of direct injury to the gland. One study observed that MRI diffusion findings consistent with pituitary ischemia were more significant in patients with PTHP. Finally, decreased pituitary volume on MRI, likely due to atrophy, has also been linked to PTHP.^1,2

Professional issues

Given the profound impact that PTHP can have on QoL, providers must thoughtfully balance diagnostic uncertainty with proactive screening in high-risk patient populations. Failure to identify treatable hormonal abnormalities may worsen disability, QoL, and complicate restoration of function and autonomy after TBI.

Rehabilitation Management and Treatments

Available or current treatment guidelines (Who needs to be tested and when)

Recommendations regarding the target population and timing of screening for PTHP are variable. The decision to screen for neuroendocrine dysfunction should be individualized, considering the severity of injury, high-risk features of the patient, and persistent or emerging symptoms of hypopituitarism.⁷

At different disease stages

Consensus guidelines recommend against screening for pituitary dysfunction in all TBI patients, particularly during the acute phase, as these disturbances may be transient. However, if acute cortisol insufficiency is suspected, guidelines recommend obtaining a serum cortisol level followed by immediate initiation of empiric glucocorticoid replacement therapy as indicated. If acute CDI is suspected, clinicians should urgently administer desmopressin, involve endocrinology, and check electrolytes, glucose, creatinine, and urine/serum osmolalities. Similarly, when there is concern for acute SIADH, clinicians should rule out renal, adrenal, and thyroid dysfunction, and assess serum/urine osmolarities.⁷

In the chronic phase of TBI, untreated hypopituitarism may result in significant morbidity and worsened QoL. Consensus guidelines recommend screening for PTHP with the aforementioned laboratory studies at 3-6 months post-injury in patients who either were admitted for >48 hours due to their TBI or are experiencing ongoing symptoms of hypopituitarism. Abnormal screening results should warrant a more comprehensive assessment that may include confirmatory dynamic testing for GHD.⁷

Coordination of care

Optimal care for patients with PTHP requires interdisciplinary collaboration between physiatry, endocrinology, neurology, neuropsychology, and primary care. Active collaboration between these services, continuing medical education on PTHP for healthcare providers, dedicated patient and caregiver resources, and further research on diagnosis and management of PTHP may all improve outcomes in this vulnerable population.¹

Patient & family education

Patient and family education should emphasize that hormonal disturbances are common after TBIs and may emerge weeks to months after the initial event. Patients and families should be informed of key symptoms that warrant attention, including persistent fatigue, mood and sleep changes, cognitive difficulties, menstrual or sexual dysfunction, and excessive thirst or urination, as these may be due to underlying PTHP. Furthermore, it is important for patients and their caregivers to know that while early hormonal disturbances may be temporary, others may persist and significantly impact QoL. They should be encouraged to report new or worsening symptoms, attend scheduled follow-up visits, and know that treatments are available if deficiencies are identified.¹ 

Measurement of treatment outcomes

Measurement of treatment outcomes for PTHP after TBI involves biochemical, clinical, and functional components. Impairment-based outcomes include restoration of pituitary hormone axes, which are assessed through normalization of biochemical markers and resolution of symptoms directly attributable to specific hormonal deficits.⁹ Activity and participation outcomes are captured through validated measures and questionnaires that quantify the severity of symptom burden and independence. Environment-based outcomes include enhanced engagement in rehabilitation, reduced caregiver burden, and improved ability to navigate community and home environments as recovery progresses. Longitudinal assessments help track progress across these domains and capture both transient and evolving changes.¹⁰

Translation into practice: Practice “pearls”/performance improvement in practice (PIPs)/changes in clinical practice behaviors and skills

Clinicians should maintain a high index of suspicion for PTHP in all severities of TBI. Initiating endocrine screening for patients with suspected PTHP in the chronic phase of TBI, ensuring timely follow-up and referral. Validated symptom measures such as the Quality of Life After Brain Injury (QOLIBRI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Insomnia Severity Scale (ISS), and Rivermead Post-Concussion Symptoms Questionnaire (RPQ) may be used to capture patient-reported outcomes and differentiating neuropsychiatric and quality-of-life sequelae of TBI from symptoms of post-traumatic hypopituitarism, thereby supporting more accurate detection and targeted management. Furthermore, incorporating multidisciplinary communication enhances functional monitoring and facilitates prompt intervention when symptoms impair recovery. Clear patient and family education, consistent symptom documentation, and proactive evaluation and reassessment during rehabilitation represent practical steps that may meaningfully improve patient outcomes.

Cutting Edge/Emerging and Unique Concepts and Practice

Recognition of autoimmune mechanisms

• Some cases of chronic pituitary dysfunction may be caused by autoimmune injury. Anti-pituitary and anti-hypothalamic antibodies have been identified in certain patients and circulating microRNAs such as miRNA-3610 and miR-126-3p are being investigated as early indicators of pituitary damage. These discoveries may help explain why some patients recover normal hormone function while others develop long-term hormone deficiencies, highlighting the need for individualized care based on autoimmune risk.¹¹

Advanced neuroimaging for endocrine risk stratification 

• Modern MRI techniques (including susceptibility-weighted and diffusion imaging) can now detect subtle structural changes like pituitary stalk deviation, small hemorrhages, and hypothalamic tract injury. These findings often align with hormone abnormalities and can help guide earlier diagnosis and more focused and endocrine-targeted follow-up.¹

Artificial intelligence (AI)-driven predictive models 

• AI models that combine clinical, lab, and imaging data are being developed to predict who is most likely to develop hormone deficiencies after TBI. Although this is still in early stages of its development, this technology could help automate endocrine follow-up and move care for TBI survivors toward a more personalized, data-driven management.¹²

Gaps in the Evidence-Based Knowledge

Pathophysiological mechanisms are not fully understood

• Mechanical injury, vascular compromise, inflammation, and autoimmunity all play roles in pituitary dysfunction, but their relative impact is unclear. The role of apoptosis and autophagy within the hypothalamic-pituitary-adrenal axis, along with secondary factors like hypoxia or hypotension, needs further research. Understanding how these mechanisms interact over time is essential for developing targeted therapies that can prevent or reverse chronic endocrine damage.¹³

Management guidelines are inconsistent

• There is currently not a consensus on when to start or stop hormone replacement therapy, particularly for growth hormone (GH) deficiency. Evidence supporting for cognitive and functional improvement with GH therapy is mixed, and most studies are short-term or small in scale. The impact of endocrine treatment on long-term recovery, mood, and QoL is still uncertain, emphasizing the need for larger, controlled studies.¹⁴

Overall, there’s still a lot we don’t know about neuroendocrine dysfunction after TBI. The causes are complex, diagnosis is often delayed, and reported rates vary because of inconsistent screening and follow-up. Treatment guidelines also differ, especially around when to start or stop hormone therapy. Moving forward, the field needs more consistent research and long-term data to better guide patient care and recovery.

References

1. Feldt-Rasmussen U, Klose MC. Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury. Best Pr Res Clin Endocrinol Metab. 2025;39(3):102020. doi:10.1016/j.beem.2025.102020
2. Mahajan C, Prabhakar H, Bilotta F. Endocrine Dysfunction After Traumatic Brain Injury: An Ignored Clinical Syndrome? Neurocritical Care. 2023;39(3):714-723. doi:10.1007/s12028-022-01672-3
3. Unluhizarci K, Urhan E. Epidemiology and risk factors for hypopituitarism due to traumatic brain injury. Best Pr Res Clin Endocrinol Metab. 2025;39(3):101997. doi:10.1016/j.beem.2025.101997
4. Behan LA, Phillips J, Thompson CJ, Agha A. Neuroendocrine disorders after traumatic brain injury. J Neurol, Neurosurg Psychiatry. 2008;79(7):753. doi:10.1136/jnnp.2007.132837
5. Aljboor GS, Tulemat A, Al-Saedi AR, Radoi MP, Toader C, Papacocea TM. Acute and chronic hypopituitarism following traumatic brain injury: a systematic review and meta-analysis. Neurosurg Rev. 2024;47(1):841. doi:10.1007/s10143-024-03088-3
6. Kreber LA, Griesbach GS, Ashley MJ. Detection of Growth Hormone Deficiency in Adults with Chronic Traumatic Brain Injury. J Neurotrauma. 2016;33(17):1607-1613. doi:10.1089/neu.2015.4127
7. Tan CL, Alavi SA, Baldeweg SE, et al. The screening and management of pituitary dysfunction following traumatic brain injury in adults: British Neurotrauma Group guidance. J Neurol, Neurosurg Psychiatry. 2017;88(11):971-981. doi:10.1136/jnnp-2016-315500
8. Yuen K. Growth Hormone Stimulation Tests in Assessing Adult Growth Hormone Deficiency. In: Feingold K, SF A, B A, eds. Endotext. Endotext; 2023. https://www.ncbi.nlm.nih.gov/books/NBK395585/
9. Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care. Endocr Pr. 2019;25(11):1191-1232. doi:10.4158/gl-2019-0405
10. McCrea MA, Giacino JT, Barber J, et al. Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study. JAMA Neurol. 2021;78(8):982-992. doi:10.1001/jamaneurol.2021.2043
11. Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S. Hypopituitarism. Lancet. 2024;403(10444):2632-2648. doi:10.1016/s0140-6736(24)00342-8
12. Chen A, Zhong H, Peng J, Luo T, Jun S. Machine Learning-Based Modeling for Predicting Hypopituitarism After Cranial Trauma. World Neurosurg. 2025;199:124018. doi:10.1016/j.wneu.2025.124018
13. Taheri S, Karaca Z, Mehmetbeyoglu E, et al. The Role of Apoptosis and Autophagy in the Hypothalamic-Pituitary-Adrenal (HPA) Axis after Traumatic Brain Injury (TBI). Int J Mol Sci. 2022;23(24):15699. doi:10.3390/ijms232415699
14. Haria JM, Singh NK, Kumar J, Jain SK, Pamidimarri D. Metabolic and endocrine dysfunctions in traumatic brain injury: Implications for cognitive recovery and therapeutic strategies. Behav Brain Res. 2025;493:115697. doi:10.1016/j.bbr.2025.115697

Author Disclosure

Justin Weppner, DO
Nothing to Disclose

Varun Mishra
Nothing to Disclose

Alexander Robbins
Nothing to Disclose

Tyler Shick, MD
Nothing to Disclose